Trending Topic

3D Rendered Medical Illustration of Male Anatomy - Colon Cancer; Ascending Colon.
17 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Rat sarcoma virus (RAS) proteins are a family of prototypical oncogenes frequently mutated in human cancers. Mutations in the RAS gene account for 19% of all pathogenic alterations and are the subject of extensive research in molecular and clinical oncology.1 The RAS family consists of three major isoforms, namely the Harvey rat sarcoma virus (HRAS), the neuroblastoma RAS […]

Foreword – European Oncology & Haematology, 2015;11(1):9

Michele Baccarani
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Published Online: May 26th 2015 European Oncology & Haematology, 2015;11(1):9
Select a Section…
1

Article

Areader of 20 years ago could have hardly imagined many of the contents of this issue of European Oncology & Haematology.

Twenty years ago, chronic myeloid leukemia (CML) was still treated with hydroxyurea, interferon and allogeneic stem cell transplantation, and multiple myeloma with oral low-dose melphalan and prednisone, and autologous stem cell transplantation. Veno-occlusive disease of the liver was a lethal complication of allogeneic stem cell transplantation. Hodgkin’s disease was treated, already successfully, with polychemotherapy and radiation, but at a high price of toxicity, and there was little rescue for the 20 % refractory patients.

Gastrointestinal stromal tumour (GIST) was fatal. Gefitinib was not even a dream; the targeted therapy of some lung cancer was not even imaginable. The replacement therapy of Gaucher disease was only just beginning. And precision or personalised medicine were barely believable. However, it was 20 years ago, in the last decade of the 20th century, that the bases were founded for better knowledge of the biology and the molecular causes of cancer and of many non-malignant blood disorders, leading to the identification of specific targets nd to the search of agents ‘targeting the targets’. While the content of this issue celebrates the joy and satisfaction for some patients, there is still much progress required. The limits, the weakness and the costs of these new, targeted treatments are highlighted, pointing out on one hand that research must be implemented and on the another hand that progress in treatment also requires changes and progress in health policies, as a global, unmet need. It must be borne in mind that billions of people worldwide have not yet access to any of these treatments.

The message is: we do well, but we can and we must do better. Many more cancers and genetically based blood disorders will be treated more successfully in the next couple of decades; progress that needs to be maintained and controlled.

2

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Close Popup